These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 17258707)

  • 1. Glypican-3: from the mutations of Simpson-Golabi-Behmel genetic syndrome to a tumor marker for hepatocellular carcinoma.
    Jakubovic BD; Jothy S
    Exp Mol Pathol; 2007 Apr; 82(2):184-9. PubMed ID: 17258707
    [No Abstract]   [Full Text] [Related]  

  • 2. Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more.
    Kandil DH; Cooper K
    Adv Anat Pathol; 2009 Mar; 16(2):125-9. PubMed ID: 19550373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and diagnostic value of a novel oncofetal protein: glypican 3.
    Wang SK; Zynger DL; Hes O; Yang XJ
    Adv Anat Pathol; 2014 Nov; 21(6):450-60. PubMed ID: 25299314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Simpson-Golabi-Behmel syndrome causative glypican-3, binds to and inhibits the dipeptidyl peptidase activity of CD26.
    Davoodi J; Kelly J; Gendron NH; MacKenzie AE
    Proteomics; 2007 Jun; 7(13):2300-10. PubMed ID: 17549790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Up-regulation of glypican-3 in human hepatocellular carcinoma.
    Suzuki M; Sugimoto K; Tanaka J; Tameda M; Inagaki Y; Kusagawa S; Nojiri K; Beppu T; Yoneda K; Yamamoto N; Ito M; Yoneda M; Uchida K; Takase K; Shiraki K
    Anticancer Res; 2010 Dec; 30(12):5055-61. PubMed ID: 21187490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Speech and language in Simpson-Golabi-Behmel syndrome: a case report.
    Van Borsel J; Baudonck N; Verhaaren H; Van Lierde K
    Genet Couns; 2008; 19(2):241-9. PubMed ID: 18619000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simpson Golabi Behmel syndrome: progress toward understanding the molecular basis for overgrowth, malformation, and cancer predisposition.
    DeBaun MR; Ess J; Saunders S
    Mol Genet Metab; 2001 Apr; 72(4):279-86. PubMed ID: 11286501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular carcinoma: susceptibility markers.
    Blum HE
    IARC Sci Publ; 2001; 154():241-4. PubMed ID: 11220663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Genomic analysis of hepatocellular carcinoma and its application to diagnosis].
    Murakami Y
    Nihon Rinsho; 2010 Aug; 68 Suppl 8():458-61. PubMed ID: 20979296
    [No Abstract]   [Full Text] [Related]  

  • 10. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies.
    Nassar A; Cohen C; Siddiqui MT
    Diagn Cytopathol; 2009 Sep; 37(9):629-35. PubMed ID: 19405109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of glypican 3 in hepatoblastoma: an immunohistochemical study of 65 cases.
    Zynger DL; Gupta A; Luan C; Chou PM; Yang GY; Yang XJ
    Hum Pathol; 2008 Feb; 39(2):224-30. PubMed ID: 17949790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glypican-3 expression in benign liver tissue with active hepatitis C: implications for the diagnosis of hepatocellular carcinoma.
    Abdul-Al HM; Makhlouf HR; Wang G; Goodman ZD
    Hum Pathol; 2008 Feb; 39(2):209-12. PubMed ID: 17949778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression of glypican-3 mRNA in hepatocellular carcinoma and its significance].
    Ban KC; Cao J; Ou C; Yang C; Su JJ; Li Y; Xue HF; Duan XX
    Zhonghua Gan Zang Bing Za Zhi; 2005 Apr; 13(4):281, 285. PubMed ID: 15850517
    [No Abstract]   [Full Text] [Related]  

  • 14. Gpc-3 is a notable diagnostic, prognostic and a latent targeted therapy marker in hepatocellular carcinoma.
    Zou ZQ; Ding YP; Long B; Yuh JG; Xu AL; Lang ZW; Zou SY; Liu YD; Ding K; Li YY
    Hepatogastroenterology; 2010; 57(102-103):1285-90. PubMed ID: 21410073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples.
    Baumhoer D; Tornillo L; Stadlmann S; Roncalli M; Diamantis EK; Terracciano LM
    Am J Clin Pathol; 2008 Jun; 129(6):899-906. PubMed ID: 18480006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modern diagnosis of hepatocellular carcinoma: Utilization of liver biopsy and genomic markers.
    Marrero JA
    J Hepatol; 2009 Apr; 50(4):659-61. PubMed ID: 19237223
    [No Abstract]   [Full Text] [Related]  

  • 17. Candidate molecular markers for histological diagnosis of early hepatocellular carcinoma.
    Sakamoto M; Mori T; Masugi Y; Effendi K; Rie I; Du W
    Intervirology; 2008; 51 Suppl 1():42-5. PubMed ID: 18544947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions.
    Kandil D; Leiman G; Allegretta M; Trotman W; Pantanowitz L; Goulart R; Evans M
    Cancer; 2007 Oct; 111(5):316-22. PubMed ID: 17763368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Familial Simpson-Golabi-Behmel syndrome: studies of X-chromosome inactivation and clinical phenotypes in two female individuals with GPC3 mutations.
    Yano S; Baskin B; Bagheri A; Watanabe Y; Moseley K; Nishimura A; Matsumoto N; Ray PN
    Clin Genet; 2011 Nov; 80(5):466-71. PubMed ID: 20950395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 1 Mb-sized microdeletion Xq26.2 encompassing the GPC3 gene in a fetus with Simpson-Golabi-Behmel syndrome Report, antenatal findings and review.
    Weichert J; Schröer A; Amari F; Siebert R; Caliebe A; Nagel I; Gillessen-Kaesbach G; Mohrmann I; Hellenbroich Y
    Eur J Med Genet; 2011; 54(3):343-7. PubMed ID: 21362501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.